STOCK TITAN

Humacyte Inc - HUMA STOCK NEWS

Welcome to our dedicated news page for Humacyte (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Humacyte's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Humacyte's position in the market.

Rhea-AI Summary
Humacyte, Inc. (Nasdaq: HUMA) receives Priority Review from the FDA for its Biologics License Application (BLA) seeking approval of the Human Acellular Vessel (HAV) in urgent arterial repair following extremity vascular trauma. The BLA submission is supported by positive Phase 2/3 clinical trial results and real-world evidence from a Humanitarian Aid Program in Ukraine. The PDUFA date is set for August 10, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.79%
Tags
none
-
Rhea-AI Summary
Humacyte, Inc. (Nasdaq: HUMA) has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the Human Acellular Vessel (HAV) in urgent arterial repair following extremity vascular trauma. The submission is supported by positive results from the V005 Phase 2/3 clinical trial and outcomes of real-world use in Ukraine. The HAV demonstrated higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks. The company has requested Priority Review, and if granted, the review should be completed within six months of the filing acceptance date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Humacyte, a clinical-stage biotechnology platform company (Nasdaq: HUMA), announced that Laura Niklason, M.D., Ph.D., and Dale Sander will present at the Piper Sandler 35th Annual Healthcare Conference in New York, NY on November 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
conferences
Rhea-AI Summary
Humacyte, Inc. (Nasdaq: HUMA) announced positive Phase 2/3 clinical trial results for the Human Acellular Vessel (HAV) in treating vascular trauma, presenting higher patency rates and lower amputation and infection rates compared to synthetic graft benchmarks. The company plans to file a BLA for an indication in vascular trauma with the FDA this quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
clinical trial
-
Rhea-AI Summary
HUMA: Positive top line results from the V005 Phase 2/3 trial of the Human Acellular Vessel™ (HAV™) in vascular trauma repair. BLA for an indication in vascular trauma planned to be filed with the FDA during the current quarter. Financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights: $100.0 million cash and cash equivalents as of September 30, 2023. No revenue for the third quarter of 2023. Research and development expenses were $18.6 million for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.33%
Tags
earnings
-
Rhea-AI Summary
Humacyte, Inc. (Nasdaq: HUMA) will release its financial results for the third quarter ended September 30, 2023, on November 9, 2023. A webcast and conference call will be held at 4:30 p.m. ET to provide a corporate and financial update. Dial-in details: 1-888-999-5318 (U.S.) and 1-848-280-6460 (International). Webcast link available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
conferences earnings
Rhea-AI Summary
Humacyte to present at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
conferences
-
Rhea-AI Summary
Humacyte to host KOL event discussing clinical data from Phase 2/3 V005 trial and use of Human Acellular Vessel™ (HAV™) in repairing blood vessels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
-
Rhea-AI Summary
Humacyte announces positive top line results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair. The trial showed higher rates of patency, lower rates of amputation and infection compared to synthetic graft benchmarks. BLA planned to be filed with FDA in 4th Quarter 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.86%
Tags
clinical trial
Rhea-AI Summary
Humacyte, Inc. to announce top line data results from Phase 2/3 V005 vascular trauma clinical trial in virtual webinar. HAV receives priority designation for treatment of vascular trauma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.86%
Tags
clinical trial
Humacyte Inc

Nasdaq:HUMA

HUMA Rankings

HUMA Stock Data

470.23M
66.13M
36.08%
17.57%
5.92%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Durham

About HUMA

biotechnology company